Convergence: What's Next at the Nexus?

Convergence is the great hope of pharmaceutical and device companies hoping to enter into new high growth markets with differentiated products. Drug-eluting stents turned a stagnant product into a thriving $6 billion market, and now companies are trying to find the next large opportunity that combines devices and drugs. They're looking at many kinds of implantable devices that incorporate biomaterials and drugs to achieve site specific drug delivery, in cardiovascular disease, peripheral vascular disease, ophthalmology, orthopedics, wound healing, and anti-infection.